New Hope for Patients with Muscle and Heart Disease
Kate Therapeutics is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapy and enable the pursuit of a broader set of disease targets that are otherwise difficult to drug with current technologies. Data supporting one of our approaches to improve AAV-mediated gene delivery has been published (Tabebordbar et al., Cell, 2021). Our novel capsids provide superior muscle and heart transduction and liver de-targeting compared to the naturally occurring serotypes currently used in clinical trials. This may enable more complete tissue transduction at significantly lower and safer doses, addressing a major limitation of gene therapy.
Dedicated to the Mission
We commit to delivering transformative therapies to patients and pursuing scientific innovation with rigor, perseverance, efficiency and a sense of urgency.
Dedicated to Patients
We develop meaningful and impactful therapeutics with scientific and personal integrity. We engage the patient community to understand their needs and perspectives.
Dedicated to Our Team
We respect, encourage and help one another and hold ourselves accountable to do the right thing. We are open to diverse thoughts and communicate in a timely and transparent manner.
Dedicated to Growth
We remain curious and are open to new ideas. We develop our team’s diverse talents and, as employees, take the initiative to contribute to and help other members of the company.
We are Focused on Delivering Life-Changing Therapies to Patients
We are applying technology platforms that address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation.